AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$TGTX

TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics (TGTX) reported Q3 earnings of $55.5M, or 35 cents per share, beating analyst estimates of 28 cents. Revenue was $259.9M, exceeding forecasts of $247.2M. The results surpassed Wall Street expectations.

Original reporting
finance.yahoo.com
Published Nov 9, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TG Therapeutics: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TGTXBullishMed
01

Why it matters

Earnings beat could attract short‑term buying interest and support the stock price.

02

Market read

First‑report earnings beat for a small‑cap biotech, offering a modest trading opportunity.

03

What to watch

Potential headwinds from upcoming pipeline milestones not discussed.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

TG Therapeutics is a biopharmaceutical company focused on hematology and oncology.

Company-level read

Ticker impact

$TGTXBullishHigh confidence
Context

TG Therapeutics reported Q3 earnings of $55.5M, net income $0.35/share beating Zacks estimates of $0.28/share.

Expected impact

likely upside as the market prices in the earnings beat

Evidence & confidence

The company exceeded both earnings and revenue expectations, a fresh primary disclosure that can move the share price today.

Market effects

Sector

Biopharma sector may see modest lift from a small‑cap earnings beat.

Regional

North Carolina biotech cluster gains visibility.

Global

Limited; impact confined to TG Therapeutics and peers.

Counterpoint

What could challenge this read

The beat may be priced in quickly, limiting upside.

Key entities

  • Company
    TG Therapeutics Inc.

    Biopharma firm reporting Q3 results.

Read at source← All news

StoryTG Therapeutics posts Q3 revenue beat, raises full‑year revenue guidance to about $1 billion

Also covered by

3 outlets

Related articles

$TGTXLow

TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript

TG Therapeutics (TGTX) reported $1B annual revenue, highlighting progress with BRIUMVI. Key updates include seven-year clinical data, real-world evidence, and potential approvals for simplified IV dosing and self-administered subcutaneous BRIUMVI by 2028. The company also presented early results for azer-cel in progressive MS, aiming to expand its MS treatment portfolio.

finance.yahoo.com
$TGTXMedAI 8/10

What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call

TG Therapeutics (TGTX) reported on its Q3 earnings call, highlighting progress in developing a simplified intravenous regimen for BRIUMVI, with a potential label update targeted for mid-2027. The company also discussed a self-administered subcutaneous version, aiming for a 2028 launch. Long-term data showed positive results for BRIUMVI, and early-stage data for azer-cel, a CAR T-cell therapy, indicated stable or improved disability scores in 90% of patients.

finance.yahoo.com
$TGTXHighAI 8/10

TG Therapeutics Raises 2026 Revenue Guidance to About $1 Billion

TG Therapeutics reported Q3 2026 revenue of $259.9M and net income of $55.5M. The company raised its 2026 revenue guidance to $1B and BRIUMVI U.S. net product revenue to $915M-$920M. Cash and investments totaled $556.7M. BRIUMVI showed strong performance, with increased targets supported by IV business momentum. Clinical trials for BRIUMVI and Azer-cel are ongoing.

tradingview.com
$TGTXHighAI 8/10

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

TG THERAPEUTICS, INC. (TGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue

SEC EDGAR 8-K